diflyukan-kaps-150mg-n12

60.00$

Category:

Product Description

diflyukan-kaps-150mg-n12

FREE SHIPPING TO ALL COUNTRIES!!!

I ACCEPT PAYPAL
SHIPPING: 
Europe delivered time is 8 — 12 business days.

Usa/canada delivered time 15-20 business days.

Australia/Asia delivered time 15-26 business days.

For any possible questions, please, contact me! 
NEW 
100 % ORIGINAL 
TRACKING NUMBER 
THANK YOU FOR VISITING MY LOT 
It is very important !!! Item will be shipped from Russia for 2-3 days and free shipping takes 14 to 21 days

Free shipping

NEW 
100 % ORIGINAL

TRACKING NUMBER

THANK YOU FOR VISITING MY LOT

Composition Each capsule contains: active substance: fluconazole 150 mg; excipients: lactose 149,123 mg, corn starch 49,5 mg, silicon dioxide colloidal 0,352 mg, magnesium stearate 3,173 mg, sodium lauryl sulfate 0,352 mg; capsule shell: titanium dioxide (E171) 1,47 %, blue patent dye (E 131) 0,03 %, gelatin up to 100 %. Ink for labeling capsules 50 mg, 100 mg and 150 mg: shellac glaze 63 %, iron oxide black (E172) 25 %, N-butyl alcohol 8,995 %, industrial methylated alcohol 74 OR 2 %, soy lecithin 1 %, anti-foam component DC 1510 0,005 %. Pharmacodynamics fluconazole, a triazole antifungal agent, is a potent selective inhibitor of Sterol synthesis in the fungal cell. Fluconazole has demonstrated activity in vitro and in clinical studies against most of the following microorganisms: Candida albicans, Candida glabrata (many strains are moderately sensitive), Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans. Fluconazole activity has been shown in vitro against the following microorganisms, but the clinical significance of this is unknown: Candida dubliniensis, Candida guilliermondii, Candida kefyr, Candida lusitaniae. When taken orally, fluconazole is active on various models of fungal infections in animals. The activity of the drug in opportunistic mycoses, including those caused by Candida spp, has been demonstrated. (including generalized candidiasis in animals with suppressed immunity), Cryptococcus neoformans (including intracranial infections), Microsporum spp. and Trychophyton spp. Fluconazole activity was also established in models of endemic mycoses in animals, including infections caused by Blastomyces dermatitides, Coccidioides immitis (including intracranial infections) and Histoplasma capsulatum in animals with normal and suppressed immunity.

Dosage Inside. Capsules are swallowed whole. Therapy can be started before the results of sowing and other laboratory tests. However, antifungal therapy should be changed accordingly when the results of these studies become known. When transferring the patient from intravenous to oral administration of the drug or Vice versa, changes in the daily dose is not required. The daily dose of Diflucan depends on the nature and severity of the fungal infection. In infections requiring repeated administration of the drug, treatment should be continued until the disappearance of clinical or laboratory signs of active fungal infection. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal candidiasis usually need supportive therapy to prevent relapses of infection. Use in adults 1. In cryptococcal meningitis and cryptococcal infections of other localization, 400 mg is usually used on the first day, and then treatment is continued at a dose of 200-400 mg once a day. The duration of treatment for cryptococcal infections depends on the presence of clinical and mycological effects; in cryptococcal meningitis, treatment is usually continued for at least 6-8 weeks. In cases of life-threatening infections, the daily dose can be increased to 800 mg. to prevent recurrence of cryptococcal meninigitis in patients at high risk of recurrence, after completion of the full course of primary treatment, Diflucan therapy at a dose of 200 mg/day can be continued for an indefinite period of time. 2. When coccidioidomycosis may require the use of the drug at a dose of 200-400 mg/day. For some infections, especially with lesions of the meninges, a dose of 800 mg per day may be considered. The duration of therapy is determined individually, can last up to 2 years; it is 11-24 months with coccidioidomycosis, 2-17 months — with paracoccidioidomycosis, 1-16 months — with sporotrichosis and 3-17 months — with histoplasmosis. 3. In candidemia, disseminated candidiasis and other invasive candidiasis infections, the saturating dose is 800 mg on the first day, followed by a dose of 400 mg/day. The duration of therapy depends on the clinical efficacy. The General recommendation for the duration of treatment of candidemia is 2 weeks after the first negative result of blood culture and the disappearance of signs and symptoms of candidemia. Treatment of mucous candidiasis in oropharyngeal candidiasis, the saturating dose is 200-400 mg on the first day, the subsequent dose: 100-200 mg once a day for 7-21days. If necessary, patients with severe suppression of immune function treatment can be continued for a longer time. In atrophic oral candidiasis associated with the wearing of dentures, the drug is usually used in a dose of 50 mg once a day for 14 days in combination with local antiseptic agents for the treatment of the prosthesis. In candiduria, the effective dose is usually 200-400 mg/day with a duration of treatment of 7-21 days. In patients with severe impairment of immune system function, longer periods of therapy can be used. In chronic skin-mucous candidiasis, 50-100 mg per day is used up to 28 days of treatment. Depending on the severity of the infection treatment or the concomitant immune system disorder and infection, longer periods of therapy may be used. With candidiasis of the esophagus, the saturating dose is 200-400 mg on the first day, the subsequent dose is 100-200 mg per day. The course of treatment is 14-30 days (until remission of esophageal candidiasis). If necessary, patients with severe suppression of immune function treatment can be continued for a longer time. To prevent relapses of oropharyngeal candidiasis in HIV-infected patients with a high risk of recurrence, the drug is used 100-200 mg per day or 200 mg 3 times a week for an indefinite period of time in patients with chronically reduced immunity. To prevent recurrence of esophageal candidiasis in HIV-infected patients with a high risk of recurrence, the drug is used 100-200 mg per day or 200 mg 3 times a week for an indefinite period of time in patients with chronically reduced immunity. In chronic atrophic oral candidiasis associated with dental prosthesis, the drug is usually used in a dose of 50 mg once a day for 14 days in combination with local antiseptic agents for the treatment of the prosthesis. In acute vaginal candidiasis, candidiasis balanitis, the drug is used once inside at a dose of 150 mg.To reduce the frequency of recurrence of vaginal candidiasis, the drug can be used at a dose of 150 mg every three days — only 3 doses (on the 1st, 4th and 7th day), then a maintenance dose of 150 mg once a week. The maintenance dose can be applied up to 6 months. Treatment of dermatomycosis in skin infections, including dermatophytosis of the feet, dermatophytosis of the torso, inguinal dermatophytosis and Candida infections, the recommended dose is 150 mg once a week or 50 mg once a day. The duration of therapy is usually 2-4 weeks, with mycosis of the feet may require longer therapy up to 6 weeks. With lichen mottled, the recommended dose is 300-400 mg once a week for 1-3 weeks. An alternative treatment regimen is to use the drug 50 mg once a day for 2-4 weeks. 4. In onychomycosis, the recommended dose is 150 mg once a week. Treatment should be continued until the infected nail is replaced (the uninfected nail grows). It usually takes 3-6 months and 6-12 months, respectively, to re-grow nails on the fingers and feet. However, the rate of growth can vary widely in different people, as well as depending on age. After successful treatment of long-lasting chronic infections, sometimes there is a change in the shape of the nails. 5. To prevent candidiasis in patients with malignant tumors, the recommended dose of Diflucan is 200-400 mg once a day, depending on the risk of fungal infection. For patients at high risk of generalized infection, for example, with severe or long-lasting neutropenia, the recommended dose is 400 mg once a day. Diflucan is used a few days before the expected development of neutropenia and, after an increase in the number of neutrophils more than 1000 in mm3, treatment is continued for another 7 days. Use in children As with similar infections in adults, the duration of treatment depends on the clinical and mycological effect. For children, the daily dose of the drug should not exceed that for adults. Diflucan is used daily once a day. In mucosal candidiasis, the recommended dose of Diflucan is 3 mg / kg / day. On the first day, in order to achieve an equilibrium concentration more quickly, a shock dose of 6 mg/kg can be applied.for the treatment of invasive candidiasis and cryptococcal meningitis, the recommended dose is 6-12 mg/kg/day, depending on the severity of the disease. To suppress the recurrence of cryptococcal meningitis in children with AIDS, the recommended dose of Diflucan is 6 mg / kg / day. For the prevention of fungal infections in children with suppressed immunity, whose risk of infection is associated with neutropenia, developing as a result of cytotoxic chemotherapy or radiation therapy, the drug is used for 3-12 mg/kg / day, depending on the severity and duration of preservation of induced neutropenia (see dose for adults; for children with renal failure — see dose for patients with renal failure). In case of impossibility of proper use in children dosage forms drug Diflucan capsules should consider replacement with other dosage forms of the drug (powder for preparation of suspension for oral or intravenous) in equivalent doses. Use in the elderly in the absence of signs of renal failure Diflucan is used in the usual dose. In patients with renal insufficiency (creatinine clearance <50 ml / min), the dose is adjusted as described below. Use in patients with renal insufficiency with a single dose change is not required. In patients (including children) with impaired renal function with repeated use of the drug should initially introduce a shock dose of 50 mg to 400 mg, after which the daily dose (depending on the indication) is set according to the following table (see instructions) Patients on regular dialysis should receive 100% of the recommended dose after each dialysis session. On the day when dialysis is not performed, patients should receive a reduced (depending on creatinine clearance) dose of the drug. In children with impaired renal function, the daily dose of the drug should be reduced in the same proportion as in adults), according to the severity of renal failure.